|
|
|
(Journal Article): Response to the Comment by D. Bresson and M. von Herrath
Chatenoud L, Bach JF (Université René Descartes Paris 5, INSERM U580, Hôpital Necker-Enfants Malades, Paris, France,
bach(at)necker.fr
)
IN:
Rev Diabetic Stud
2005; 2(4):190-191
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)
Fulltext:
HTML
PDF
ABSTRACT: n.a.
TYPE OF PUBLICATION: Comment
REFERENCES:
- Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992. 41:385-391.
- Chatenoud L, Thervet E, Primo J, Bach JF. Rémission de la maladie établie chez la souris NOD diabétique par l'anticorps monoclonal anti-CD3. C. R. Acad. Sci. III 1992. 315:225-228.
- Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 1994. 91:123-127.
- Von Herrath MG, Coon B, Wolfe T, Chatenoud L. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J. Immunol. 2002. 168:933-941.
|
Respond
on this Journal Article!
Hint: Your Response should directly apply to Response to the Comment by D. Bresson and M. von Herrath.
Please check, if this context applies best to your contribution. Otherwise click HERE to change to the appropriate
subject area. The actual subject area is Anti-CD3 Therapy.
|
|
|
|
|
